Tracers / [225Ac]Ac-3p-C-DEPA-NO2

[225Ac]Ac-3p-C-DEPA-NO2

Also written as [Ac-225]Ac-3p-C-DEPA-NO2
Radionuclide
Ac-225 t½ 14284.8 min
Modality
Therapy
Production route
Stage
preclinical study
Syntheses indexed
1

What it is

Compound class
DEPA-based bifunctional chelator (decadentate macrocyclic ligand) for radiometal labelling
Target / mechanism
Clinical application
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisSPE93.7 to 96.8%3p-C-DEPA-NO241428153
2025 EJNMMI Radiopharm Chem
The radiolabelling experiments were performed by reacting 90–100 kBq of [225Ac]Ac(NO3)3 — Excellent radiochemical conversions (RCCs) were achieved for [225Ac]Ac-3p-C-DEPA-NO2 across a range of concentrations (0.7- 13.4 µg) with high RCC’s (93.7 to 96.8%) after 1 h at room temperature.

Need this precursor?We can point you to suppliers for [225Ac]Ac-3p-C-DEPA-NO2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41428153. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41428153: '3p-C-DEPA-NO2 (1, 2- [(carboxymethyl)] [5-(4-nitrophenyl-1-[4, 7, 10-tris(carboxymethyl) -1, 4, 7, 10- tetraazacyclododecan-1-yl]pentan-2-yl)amino]acetic acid), is a decadentate ligand'. Stage set/updated at stage 23 from PMID 41428153: 'Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.'.